Willem van Weperen is a senior biotech leader focused on building and leading teams to develop and commercialize rare disease therapies for patients. Currently, Willem is the CEO of Pluvia Biotech, developing therapies for patients with PKU. In his early career Willem held several roles in Genzyme, pioneering the rare disease business model. Subsequently, Willem was several years CEO of early-stage CNS company to-BBB, which was followed by senior commercial leadership roles at rare disease companies Prosensa, Amicus, Myokardia and Intercept. Willem holds a MSc in Biomedical Sciences from Utrecht University and an MBA from Bradford University.